Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice

J. E. Arends; P. A M Kracht; A. I M Hoepelman

doi:10.1016/j.cmi.2016.05.027

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice

J. E. Arends^*, P. A M Kracht, A. I M Hoepelman

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

1 Citation (Scopus)

Abstract

In recent years a revolution in hepatitis C virus drug development has taken place from troublesome regimens with pegylated interferon-alfa for 24 to 48 weeks with limited success to all-oral single tablet regimens taken for 12 weeks with very high chances of success. These promising results are not available to everybody. Depending on, for example, geographical factors with limited availability of new compounds, virus factors like hepatitis C virus genotype and host factors like presence of cirrhosis, these favorable outcomes can be compromised. This review discusses the recent clinical trials (from phase 3 registration through real-world application), highlighting the different available regimens and their success rates.

Original language	English
Pages (from-to)	846-852
Number of pages	7
Journal	Clinical Microbiology and Infection
Volume	22
Issue number	10
DOIs	https://doi.org/10.1016/j.cmi.2016.05.027
Publication status	Published - 1 Oct 2016

Keywords

Clinical trials
DAA
Direct-acting antivirals
HCV treatment
Hepatitis C virus

Access to Document

10.1016/j.cmi.2016.05.027

Cite this

@article{b8e65d0d19d84ff4a6e37386a4b93383,

title = "Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice",

abstract = "In recent years a revolution in hepatitis C virus drug development has taken place from troublesome regimens with pegylated interferon-alfa for 24 to 48 weeks with limited success to all-oral single tablet regimens taken for 12 weeks with very high chances of success. These promising results are not available to everybody. Depending on, for example, geographical factors with limited availability of new compounds, virus factors like hepatitis C virus genotype and host factors like presence of cirrhosis, these favorable outcomes can be compromised. This review discusses the recent clinical trials (from phase 3 registration through real-world application), highlighting the different available regimens and their success rates.",

keywords = "Clinical trials, DAA, Direct-acting antivirals, HCV treatment, Hepatitis C virus",

author = "Arends, {J. E.} and Kracht, {P. A M} and Hoepelman, {A. I M}",

year = "2016",

month = oct,

day = "1",

doi = "10.1016/j.cmi.2016.05.027",

language = "English",

volume = "22",

pages = "846--852",

journal = "Clinical Microbiology and Infection",

issn = "1198-743X",

publisher = "Elsevier",

number = "10",

}

TY - JOUR

T1 - Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice

AU - Arends, J. E.

AU - Kracht, P. A M

AU - Hoepelman, A. I M

PY - 2016/10/1

Y1 - 2016/10/1

N2 - In recent years a revolution in hepatitis C virus drug development has taken place from troublesome regimens with pegylated interferon-alfa for 24 to 48 weeks with limited success to all-oral single tablet regimens taken for 12 weeks with very high chances of success. These promising results are not available to everybody. Depending on, for example, geographical factors with limited availability of new compounds, virus factors like hepatitis C virus genotype and host factors like presence of cirrhosis, these favorable outcomes can be compromised. This review discusses the recent clinical trials (from phase 3 registration through real-world application), highlighting the different available regimens and their success rates.

AB - In recent years a revolution in hepatitis C virus drug development has taken place from troublesome regimens with pegylated interferon-alfa for 24 to 48 weeks with limited success to all-oral single tablet regimens taken for 12 weeks with very high chances of success. These promising results are not available to everybody. Depending on, for example, geographical factors with limited availability of new compounds, virus factors like hepatitis C virus genotype and host factors like presence of cirrhosis, these favorable outcomes can be compromised. This review discusses the recent clinical trials (from phase 3 registration through real-world application), highlighting the different available regimens and their success rates.

KW - Clinical trials

KW - DAA

KW - Direct-acting antivirals

KW - HCV treatment

KW - Hepatitis C virus

UR - http://www.scopus.com/inward/record.url?scp=84995699956&partnerID=8YFLogxK

U2 - 10.1016/j.cmi.2016.05.027

DO - 10.1016/j.cmi.2016.05.027

M3 - Article

C2 - 27297320

AN - SCOPUS:84995699956

SN - 1198-743X

VL - 22

SP - 846

EP - 852

JO - Clinical Microbiology and Infection

JF - Clinical Microbiology and Infection

IS - 10

ER -

Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this